Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Children's Oncology Group
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
University of Nebraska
Eli Lilly and Company
Hoffmann-La Roche
Jazz Pharmaceuticals
ITM Solucin GmbH
National Cancer Institute (NCI)
University of Southern California
National Institutes of Health Clinical Center (CC)
Eli Lilly and Company
Medical College of Wisconsin
BeiGene
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Catalysis SL
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
UNICANCER
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
Eisai Inc.
Canadian Cancer Trials Group
Canadian Cancer Trials Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
M.D. Anderson Cancer Center
Children's Oncology Group
CHA University
Rush University Medical Center
Radiation Therapy Oncology Group
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Radiation Therapy Oncology Group
Radiation Therapy Oncology Group
Radiation Therapy Oncology Group
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Case Comprehensive Cancer Center
Massachusetts General Hospital